Hong Kong Food Stock News

What the EU approval could mean for Hansoh Pharmaceutical Group (SEHK:3692) The European Commission’s approval of Hansoh Pharmaceutical Group (SEHK:3692)’s Aumolertinib Mesylate Tablets for specific advanced non small cell lung cancer patients takes Ameile and Aumseqa beyond China and into a major new market. This decision, following a positive view from the European Medicines Agency’s Committee for Medicinal Products for Human Use, adds an EU indication for both first line EGFR mutated NSCLC...

What ZJLD’s profit warning means for shareholders ZJLD Group (SEHK:6979) has warned that 2025 revenue and profit are expected to fall by more than half, citing weaker baijiu demand and its own decision to cut channel inventory. At the same time, the company is pushing its Premier Retailers Alliance model and extending distribution into county and rural markets. It is aiming to reset how it reaches consumers and uses its sales network. See our latest analysis for ZJLD Group. Against this...

TCL Electronics Holdings (SEHK:1070) has been promoted to the Hang Seng Composite LargeCap & MidCap Index. This change can influence passive fund flows and investor attention around the stock. See our latest analysis for TCL Electronics Holdings. The index promotion comes after a period of firm share price momentum, with TCL Electronics Holdings posting a 90 day share price return of 20.16% and a year to date share price return of 17.29%. The 1 year total shareholder return stands at 79.59%...

The Hong Kong government recently raised stamp duty on residential properties valued above HK$100,000,000 to 6.5% and outlined plans to bring REITs under mutual-market access while potentially exempting some non-residential property transfers from stamp duty. These policy moves could reshape how developers like Hang Lung Properties balance high-end residential exposure with participation in an evolving REIT and commercial property framework. We’ll now examine how the higher stamp duty on...

SUNeVision Holdings (SEHK:1686) is back in focus after reporting half year results to December 31, 2025, with higher sales, net income and earnings per share, supported by demand for premium data centre capacity. See our latest analysis for SUNeVision Holdings. The latest results land after a strong run in the share price, with a 90 day share price return of 32.42% and a year to date gain of 41.60%, even though the 1 year total shareholder return is 21.68% lower. That mix points to momentum...

JNBY Design (SEHK:3306) is back in focus after reporting higher first half 2026 revenue, profit and margins, alongside stronger operating cash flow and a higher interim dividend that reinforces its emphasis on shareholder returns. See our latest analysis for JNBY Design. The latest set of results and dividend news comes after a period of positive market interest, with a 30 day share price return of 12.55% and a 1 year total shareholder return of 59.93%. The 3 year total shareholder return of...

Yangtze Optical Fibre and Cable recently announced it will showcase its latest AI‑oriented optical connectivity solutions at MWC Barcelona 2026, including a dedicated March 4 launch event for its hollow‑core fibre technology. This focus on hollow‑core fibre, which is designed to deliver lower latency, higher transmission efficiency and improved signal quality, highlights YOFC’s bid to support next‑generation ultra‑high‑speed data and AI computing networks. We’ll now examine how this...

WuXi XDC Cayman (SEHK:2268) just expanded its ADC platform reach as Earendil Labs secured an exclusive global license to the WuXiTecan-2 payload-linker technology, structured with upfront, milestone and royalty economics. See our latest analysis for WuXi XDC Cayman. The Earendil Labs agreement, which highlights WuXi XDC Cayman’s ADC and payload platform, comes as the shares trade at HK$63.15, with a 1 day share price return of 8.23%, a 30 day share price return of 2.02%, and a 1 year total...

Intro Sino Land (SEHK:83) has opened H1 2026 earnings season with a set of numbers that put revenue and EPS firmly in focus, as investors weigh how the latest figures square with expectations for a business priced at HK$12.78 per share. The company has seen half year revenue move from HK$3,842 million in H2 2024 to HK$3,854 million in H1 2025 and HK$4,329 million in H2 2025, while basic EPS over those periods came in at HK$0.2082, HK$0.209 and HK$0.243 respectively. This gives a clear line of...

Xinyi Glass Holdings (SEHK:868) has put fresh numbers on the table for FY 2025, with first half revenue of C¥9.8b and basic EPS of C¥0.23, setting the tone for how the rest of the year might shape up. The company has seen revenue move from C¥10.9b in the first half of 2024 to C¥9.8b in the latest half, while EPS has shifted from C¥0.59 to C¥0.23. These shifts sit against trailing twelve month EPS of C¥0.62 on revenue of C¥20.8b. With trailing net margin at 13.1% versus 15.1% a year earlier,...

Plover Bay Technologies (SEHK:1523) has opened FY 2025 with first half revenue of US$62.9 million and basic EPS of US$0.019649, setting a clear marker for how the year is shaping up. The company has seen revenue move from US$57.3 million in the first half of 2024 to US$59.5 million in the second half and then to US$62.9 million in the first half of 2025. Basic EPS has tracked from US$0.017356 to US$0.0172 and then to US$0.019649 over the same periods, giving investors a clear view of the top...

Shanghai Henlius Biotech (SEHK:2696) has caught investor attention after a strong 1 year total return of 144%, alongside revenue of CN¥5,797.88 and net income of CN¥824.30, prompting closer scrutiny of its valuation. See our latest analysis for Shanghai Henlius Biotech. Despite a recent 7 day share price return of 7.2% decline and some short term volatility, Shanghai Henlius Biotech’s 1 year total shareholder return of 144.26% and very large 3 year total shareholder return suggest momentum...

361 Degrees International (SEHK:1361) has drawn fresh attention after recent share price moves, prompting investors to reassess how its current valuation lines up with its reported earnings, revenue profile, and longer term return record. See our latest analysis for 361 Degrees International. The latest move to HK$5.65 caps a steady year to date share price return of 5.02%, while the 1 year total shareholder return of 47% and 5 year total shareholder return of 194.4% point to strong longer...

Context for BYD’s recent share performance BYD (SEHK:1211) has drawn investor attention after a period where the share price showed a 7.6% decline over the past month and a 2.6% decline over the past 3 months. See our latest analysis for BYD. Looking beyond the recent 7.6% one month share price decline, BYD’s 1 year total shareholder return of 22.5% decline contrasts with a 30.47% gain over three years and 50.87% over five years. This suggests that longer term momentum has cooled. If this...

Xiaomi has taken its tariff and royalty dispute to India's Supreme Court, challenging a tribunal ruling on how certain payments tied to imports should be taxed. The case centers on whether royalty payments linked to technology and brand use should be added to the customs value of imported components. The outcome could shape future tax treatment for contract manufacturing arrangements used by Xiaomi and other multinational producers in India. Xiaomi, traded as SEHK:1810, is contesting this...

Tongguan Gold Group (SEHK:340) drew fresh attention after issuing 2025 earnings guidance, projecting profit attributable to owners of HK$820 million to HK$840 million, including about HK$55 million of non operating derivative related expenses. See our latest analysis for Tongguan Gold Group. The strong 2025 earnings guidance has arrived after a period of intense momentum, with a 90 day share price return of 39.15% and a very large 1 year total shareholder return. The latest 1 day move of...

Why the Crescent Biopharma partnership matters for Sichuan Kelun-Biotech Biopharmaceutical The new collaboration between Crescent Biopharma and Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) on next generation oncology drugs, including joint clinical trials, is drawing fresh attention from investors to Kelun-Biotech's pipeline and funding position. See our latest analysis for Sichuan Kelun-Biotech Biopharmaceutical. At the latest share price of HK$387.4, Sichuan Kelun-Biotech...

MiniMax Group stock moves after sharp month-long rally MiniMax Group (SEHK:100) has drawn fresh attention after a sharp move in its share price over the past month, prompting investors to reassess the newly listed AI foundation model developer. See our latest analysis for MiniMax Group. The latest pullback, including a 3.17% 1 day share price return decline and 21.29% 7 day share price return decline, comes after a 56.45% 30 day and 121.30% year to date share price return. This suggests...

Recent share move and business snapshot Ascentage Pharma Group International (SEHK:6855) has seen its share price move recently, with a 1 day return of about 1.4% and a decline of roughly 26.9% over the past 3 months, drawing attention to its clinical stage biotech profile. See our latest analysis for Ascentage Pharma Group International. Looking beyond the latest move, the share price has recorded a 4.9% decline over the past month and a 26.9% decline over the past quarter, while the 1 year...

China Qinfa Group (SEHK:866) has issued new earnings guidance, telling investors to expect a loss after taxation of not more than CN¥98,000,000 for 2025, compared with a profit of about CN¥556,370,000 in 2024. See our latest analysis for China Qinfa Group. The earnings guidance sits against a very strong recent run in the stock, with a 1-day share price return of 8.09% and a year to date share price return of 41.67%. The 1-year total shareholder return is very large and multi year total...

CSPC Pharmaceutical Group (SEHK:1093) has received regulatory clearance for two long-acting drug candidates, including a monthly GLP-1/GIP injection in the US and a week-long ropivacaine pain therapy trial in China. See our latest analysis for CSPC Pharmaceutical Group. These trial approvals arrive after a strong 116.18% 1-year total shareholder return and a 25.16% 90-day share price return, although the 30-day share price return of 6.16% and recent 7-day weakness suggest shorter term...

JPMorgan’s upgrade of Cathay Pacific Airways (SEHK:293), which followed the expiry of its buyback plan on 24 February 2026, has put fresh attention on the airline’s balance sheet, cash generation, and sizeable aircraft commitments. See our latest analysis for Cathay Pacific Airways. At a share price of HK$14.06, Cathay Pacific’s recent 7 day share price return of 10.53% and 90 day share price return of 16.58% sit alongside a 1 year total shareholder return of 46.56%. This suggests momentum...

CALB Group (SEHK:3931) has issued a profit alert indicating an expected 140% to 160% increase in its 2025 net profit, citing stronger sales of advanced batteries for passenger vehicles, commercial applications, and energy storage systems. See our latest analysis for CALB Group. The profit alert lands after a mixed period for the stock, with a 30 day share price return of 4.51% and a 90 day share price decline of 8.53%, while the 1 year total shareholder return of 59.66% points to stronger...

Grand Pharmaceutical Group (SEHK:512) has drawn investor attention after posting annual revenue of HK$11,704.979 million and net income of HK$2,079.449 million, putting fresh focus on how its diversified healthcare business is currently valued. See our latest analysis for Grand Pharmaceutical Group. At a share price of HK$7.83, Grand Pharmaceutical Group has seen short term share price pressure, with a 90 day share price return decline of 4.74%. However, its 1 year total shareholder return of...